Diffuse large B-cell lymphoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 42
• CD20 22
• BCL-2 13
• MYC 10
• PD-1 12
• BTK 10
• TP53 7
• PD-L1 3
• CD22 7
• STAT3 0
• CD30 5
• CD47 0
• PI3K 0
• EZH2 1
• LAG-3 0
• ALK 0
• CTNNB1 0
• JAK 0
• STING 0
• BCMA 2
• EGFR 0
• METTL3 0
• mTOR 0
• AKT 0
• CD38 0
• IL-6 0
• JNK 0
• MMP-9 0
• PKM2 0
• PRMT5 0
• TIGIT 1
• TIM-3 0
• ABL1 0
• ARID1A 1
• ATM 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD40 0
• CDKN2A 0
• CTLA-4 0
• CXCR4 0
• FGFR 0
• FTO 0
• GPX4 0
• HDAC 0
• IL-1 0
• IL-15 0
• MYCN 0
• NLRP3 0
• NOTCH1 1
• PARP 0
• PINK1 0
• PPAR 0
• RAS 0
• SHP2 0
• SIRT1 0
• TERT 0
• TFEB 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma (LINK-M)

  Luxembourg Institute of Health· Strassen, Luxembourg· EU contribution €216,240· until Aug 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Development and characterization of a novel CAR T-cell therapy for NHL (CARLY)

  Fundacio Institut de Recerca Contra la Leucemia Josep Carreras· Badalona, Spain· EU contribution €226,441· until Jun 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune Microenvironment (CAR-TIME)

  Eberhard Karls Universitaet Tuebingen· Tuebingen, Germany· EU contribution €1,499,875· until Dec 2028

  The disease is named only in the funder's project summary, not in the title.

4 of 4 running projects, newest first. Listed amounts together: €2.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 49
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 4
• Flow Cytometry 7
• Immunohistochemistry 36
• Liquid Biopsy 1
• Circulating Tumor DNA 12
• Xenograft Model Antitumor Assays 31
• Positron-Emission Tomography 15
• Magnetic Resonance Imaging 29
• Machine Learning 11
• Deep Learning 9
• Cohort Studies 15
• Genome-Wide Association Study 4

• When lymphoma masquerades as carcinoma: A rare case of primary nasopharyngeal diffuse large B-cell lymphoma with aberrant p63 expression.

  Indian J Pathol Microbiol, Oct 2026

• Tissue-based PEG10 expression as an exploratory biomarker associated with first-line R-CHOP treatment outcome in diffuse large B-cell lymphoma.

  Future Oncol, Oct 2026

• CD19 expression is preserved following CD19-directed monoclonal antibody therapy with tafasitamab.

  Front Immunol, Sept 2026

• Pathological Diagnosis of Nodal T Follicular Helper Cell Lymphoma, Angioimmunoblastic Type.

  Pathol Int, Sept 2026

• Clinicopathological analysis of oral-cavity B-cell neoplasms: Comparison between non-immunosuppressive and immunosuppressive patients.

  J Clin Exp Hematop, Jul 2026

• Distinguishing EBV-positive classic Hodgkin lymphoma from EBV-positive DLBCL, NOS: diagnostic value and limits of immunohistochemical markers.

  Ann Diagn Pathol, Jul 2026

• A case report of primary prostate intravascular large B-cell lymphoma.

  Medicine (Baltimore), Jul 2026

• AID and MUM1 Negativity Identifies a Prognostically Favorable Subgroup of Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With Double-Hit MYC and BCL2 or BCL6 and Triple Hit.

  Pathol Int, Jul 2026

• Challenging cases of Epstein-Barr virus positive lymphomas.

  Pol J Pathol, Jun 2026

• A "Double-Hit" Lymphoma With Plasmablastic Features and Aberrant Keratin Expression Likely Transforming From Follicular Lymphoma.

  Int J Surg Pathol, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.